{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:39:05Z","timestamp":1790959145189,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.cllc.2022.03.003","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T22:13:27Z","timestamp":1647468807000},"page":"300-310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib"],"prefix":"10.1016","volume":"23","author":[{"given":"D. Ross","family":"Camidge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9172-0035","authenticated-orcid":false,"given":"Teresa","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingel","family":"Demedts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun","family":"Grosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-7743","authenticated-orcid":false,"given":"Kathryn","family":"Mileham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7772-9030","authenticated-orcid":false,"given":"Oscar","family":"Juan-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerold","family":"Bepler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4925-8243","authenticated-orcid":false,"given":"Jonathan W","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4846-7449","authenticated-orcid":false,"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Wallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5187-167X","authenticated-orcid":false,"given":"Sameera R","family":"Wijayawardana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejing Aimee","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Wacheck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2022.03.003_bib0001","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ijc.21496","article-title":"Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers","volume":"118","author":"Shigematsu H","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cllc.2022.03.003_bib0002","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib Or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.03.003_bib0003","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced egfr mutation-positive non-small-cell lung cancer (eurtac): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2022.03.003_bib0004","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase iii study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with egfr mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.03.003_bib0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated egfr-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.03.003_bib0006","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1183\/09059180.00004614","article-title":"Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas","volume":"23","author":"Cortot AB","year":"2014","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.cllc.2022.03.003_bib0007","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","article-title":"Acquired resistance to egfr tyrosine kinase inhibitors in egfr-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation","volume":"17","author":"Oxnard","year":"2011","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.cllc.2022.03.003_bib0008","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-06-1570","article-title":"Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors","volume":"12","author":"Balak","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.03.003_bib0009","doi-asserted-by":"crossref","first-page":"20932","DOI":"10.1073\/pnas.0710370104","article-title":"MET Amplification occurs with or without T790M mutations in egfr mutant lung tumors with acquired resistance to gefitinib or erlotinib","volume":"104","author":"Bean","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cllc.2022.03.003_bib0010","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating erbb3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.cllc.2022.03.003_bib0011","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/0008-5472.CAN-09-3620","article-title":"Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency","volume":"70","author":"Mcdermott","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2022.03.003_bib0012","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1349-7006.2012.02279.x","article-title":"Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands","volume":"103","author":"Yano","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cllc.2022.03.003_bib0013","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"Jama Oncol"},{"key":"10.1016\/j.cllc.2022.03.003_bib0014","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.pharmthera.2013.12.014","article-title":"The MET receptor tyrosine kinase: a key player in oncogenesis and drug resistance","volume":"142","author":"Maroun","year":"2014","journal-title":"Pharmacol Ther."},{"key":"10.1016\/j.cllc.2022.03.003_bib0015","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Vande Woude GF. MET, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat Rev Mol Cell Biol."},{"key":"10.1016\/j.cllc.2022.03.003_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2004.09.044","article-title":"C-MET as a target for human cancer and characterization of inhibitors for therapeutic intervention","volume":"225","author":"Christensen","year":"2005","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cllc.2022.03.003_bib0017","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cllc.2022.03.003_bib0018","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1582-4934.2002.tb00453.x","article-title":"Activated C-MET signals through Pi3k with dramatic effects on cytoskeletal functions in small cell lung cancer","volume":"6","author":"Maulik","year":"2002","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.cllc.2022.03.003_bib0019","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1158\/1078-0432.CCR-10-2277","article-title":"Rebiopsy of lung cancer patients with acquired resistance to egfr inhibitors and enhanced detection of the t790m mutation using a locked nucleic acid-based assay","volume":"17","author":"Arcila","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.03.003_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12885-015-1019-1","article-title":"MET fish-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with egfr mutation","volume":"15","author":"Noro","year":"2015","journal-title":"Bmc Cancer"},{"key":"10.1016\/j.cllc.2022.03.003_bib0021","doi-asserted-by":"crossref","first-page":"75RA26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cllc.2022.03.003_bib0022","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.03.003_bib0023","doi-asserted-by":"crossref","first-page":"V851","DOI":"10.1093\/annonc\/mdz394.076","article-title":"Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRM advanced NSCLC (FLAURA): final overall survival analysis","volume":"30","author":"Ramalingam","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2022.03.003_bib0024","doi-asserted-by":"crossref","first-page":"51311","DOI":"10.18632\/oncotarget.9697","article-title":"The coexistence of met over-expression and an egfr t790m mutation is related to acquired resistance to egfr tyrosine kinase inhibitors in advanced non-small cell lung cancer","volume":"7","author":"LY","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2022.03.003_bib0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/atm.2016.12.09","article-title":"MET\/HGF pathway activation as a paradigm of resistance to targeted therapieS","volume":"5","author":"Ko","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.cllc.2022.03.003_bib0026","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1158\/1078-0432.CCR-14-0543","article-title":"LY2875358, a neutralizing and internalizing anti-met bivalent antibody, inhibits HGF-dependent and HGF-independent met activation and tumor growth","volume":"20","author":"Liu","year":"2014","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.cllc.2022.03.003_bib0027","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1158\/1078-0432.CCR-16-1418","article-title":"A first-in-human phase i study of a bivalent met antibody, Emibetuzumab (LY2875358), as monotherapy and in combination with erlotinib in advanced cancer","volume":"23","author":"Rosen","year":"2017","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.cllc.2022.03.003_bib0028","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2012.47.4189","article-title":"Randomized phase ii trial of onartuzumab in combination with erlotinib in patients with advanced non\u2013small-cell lung canceR","volume":"31","author":"Spigel","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cllc.2022.03.003_bib0029","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","article-title":"Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non\u2013small-cell lung cancer","volume":"28","author":"Jackman","year":"2009","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.cllc.2022.03.003_bib0030","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American joint committee on cancer: the 7th edition of the ajcc cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cllc.2022.03.003_bib0031","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"new response evaluation criteria in solid tumours: revised recist guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2022.03.003_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","article-title":"Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products","volume":"289","author":"Mire-Sluis","year":"2004","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.cllc.2022.03.003_bib0033","first-page":"24106","article-title":"Assay development and validation for immunogenicity testing of therapeutic protein products: guidance for industry","volume":"81","year":"2016","journal-title":"Federal Register"},{"key":"10.1016\/j.cllc.2022.03.003_bib0034","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/his.12510","article-title":"Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (met)","volume":"65","author":"Gruver","year":"2014","journal-title":"Histopathology"},{"key":"10.1016\/j.cllc.2022.03.003_bib0035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/JTO.0b013e3181f7c6d4","article-title":"Treatment-by-histology interaction analyses in three phase iii trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer","volume":"6","author":"Scagliotti","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.03.003_bib0036","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1158\/1078-0432.CCR-12-2605","article-title":"Targeted met inhibition in castration-resistant prostate cancer: a randomized phase ii study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone","volume":"19","author":"Ryan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.03.003_bib0037","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2012.47.4189","article-title":"Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer","volume":"31","author":"Spigel","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.03.003_bib0038","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S2213-2600(20)30154-5","article-title":"Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with met overexpression or met amplification and acquired resistance to previous egfr inhibitor (insight study): an open-label, phase 1b\/2, multicentre, randomised trial","volume":"8","author":"Wu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cllc.2022.03.003_bib0039","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1158\/0008-5472.CAN-16-1944","article-title":"Met exon 14 mutation encodes an actionable therapeutic target in lung adenocarcinoma","volume":"77","author":"Lu","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2022.03.003_bib0040","doi-asserted-by":"crossref","first-page":"142","DOI":"10.21037\/atm.2018.04.28","article-title":"Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer","volume":"6","author":"Gkolfinopoulos","year":"2018","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.cllc.2022.03.003_bib0041","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jtho.2019.10.003","article-title":"A randomized-controlled phase 2 study of the met antibody emibetuzumab in combination with erlotinib as first-line treatment for egfr mutation-positive nsclc patients","volume":"15","author":"Scagliotti","year":"2020","journal-title":"J Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422000390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422000390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:14:04Z","timestamp":1761506044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730422000390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1525730422000390"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2022.03.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2022.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}